A new anti-cancer drug from Novosibirsk has passed clinical trials. Another cancer treatment has successfully completed the first phase of clinical trials. This drug is being developed by scientists at the Institute of Chemical Biology and Fundamental Medicine (ICBFM) of the Siberian Branch of the Russian Academy of Sciences. The treatment is based on the genetically modified oncolytic virus VV-GMCSF-Lact, specifically designed to target cancer cells. It infiltrates the tumor and destroys it while simultaneously stimulating the patient's immune system to actively fight the disease. The study included patients with advanced breast cancer. After receiving the drug, 55% of the women experienced an improvement in their condition, and their tumors began to shrink. Observations showed that the drug is not only safe for the body but also effectively combats the disease. In addition to ICBFM scientists, specialists from the Vector Center of Rospotrebnadzor and the Oncostar company, a participant in the Skolkovo project, were involved in the drug's development. Currently, Russia is conducting numerous studies aimed at creating effective treatments for cancer. In early October, preclinical trials of a vaccine developed by the Gamaleya Center (https://t.me/c/1695022138/9910) were completed. This vaccine is expected to not only stop tumor growth but also prevent its spread to other organs. Initial patient trials are planned for 2025.